JAMA Pediatrics Journal Impact Factor & Information

Publisher: American Medical Association, American Medical Association

Journal description

The Archives of Pediatrics & Adolescent Medicine is a monthly, peer-reviewed journal for physicians and other professionals who contribute to the health of children and adolescents. The Archives provides an open forum for dialogue on a full range of clinical, scientific, advocacy, and humanistic issues relevant to the care of pediatric patients from infancy through young adulthood. The Archives is a vehicle for increased attention to adolescent health, the education of pediatric health care professionals, and disease prevention and health promotion. The Archives publishes original studies, editorials, reviews by experts, practice commentaries, case quizzes, and updates on clinical science and practice management. The "Pediatric Forum" provides our readers with opportunities to express their views. Archives incorporates AJDC, the oldest journal in US pediatric literature, which originated in 1911.

Current impact factor: 5.73

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 5.731
2013 Impact Factor 4.252
2012 Impact Factor 4.282
2011 Impact Factor 4.14
2010 Impact Factor 4.029
2009 Impact Factor 4.726
2008 Impact Factor 4.32
2007 Impact Factor 3.725
2006 Impact Factor 3.565
2005 Impact Factor 3.566
2004 Impact Factor 2.893
2003 Impact Factor 2.19
2002 Impact Factor 2.053
2001 Impact Factor 2.089
2000 Impact Factor 1.701
1999 Impact Factor 1.549
1998 Impact Factor 1.53
1997 Impact Factor 1.338

Impact factor over time

Impact factor

Additional details

5-year impact 5.49
Cited half-life 8.50
Immediacy index 0.96
Eigenfactor 0.02
Article influence 2.32
Website Archives of Pediatrics and Adolescent Medicine website
Other titles Archives of pediatrics & adolescent medicine (Online), Archives of pediatrics & adolescent medicine, Archives of pediatrics and adolescent medicine
ISSN 1538-3628
OCLC 46673663
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

American Medical Association

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Only if in receipt of funding from a not-for-profit organisation, articles can be deposited after 12 months embargo
    • On non-commercial open access repository, such as PubMed Central
    • Must link to publisher version
    • Publisher's version/PDF may be used
  • Classification
    ‚Äč white

Publications in this journal

  • JAMA Pediatrics 10/2015;

  • JAMA Pediatrics 09/2015; 169(9).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fire and health policies in the United States appear to be unbalanced. On the one hand, US regulations require the inclusion of chemical flame retardants (CFRs) in many household and clothing items with the goal of saving families from death and injury due to fires. On the other hand, there is no accompanying requirement to establish the safety of the chemicals used to achieve this goal, despite a wealth of data suggesting toxicity. 1-4 This public health paradox poses the greatest risk to children , who are more vulnerable to toxins than adults and are often exposed to CFRs during critical periods of development. 2 A repeated scenario over the last several decades has been the market introduction of a CFR that has not undergone adequate toxicological testing, followed by its removal once toxicity concerns become apparent. In many cases, the products were on the market for decades. The original case study occurred in 1977, when the Consumer Product Safety Commission, a federal agency, effectively banned the sale of children's clothing containing the CFR 2,3-dibromopropyl phosphate (bromi-nated tris), following the release of animal studies that found the chemical to be mutagenic and absorbed from fabrics. Prior to the ban, brominated tris had not been adequately tested for toxicity. Brominated tris was modified and replaced with chlorinated tris, which also was not adequately tested for toxicity but was then also found to be mutagenic, absorbed through skin, and, 1 year after its introduction, banned from use in chil-dren's clothing. Similarly, following the removal of poly-chlorinated biphenyls from the US market in 1977, a chemically related class of compounds known as the polybrominated diphenyl ethers (PBDEs) entered the marketplace and became the most commonly used household-based CFRs for several decades. In 2004, the production of several PBDEs were phased out following concerns that arose from animal tests and from human epidemiological studies suggesting associations with endocrine disruption, neurodevelopmental disorders , and cancer. 3,4 Almost 10 years after the phaseout of these PBDEs, decabromodiphenyl ether, a chemical in the PBDE group, was brought to market only to be banned by several states in 2013. 1,5 While not all CFRs
    JAMA Pediatrics 07/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children, either singly or in a medication combination. Although metabolic adverse effects have been linked to SGA use in youths, estimating the risk for type 2 diabetes mellitus, a rarer outcome, has been challenging. To determine whether SGA initiation was associated with an increased risk for incident type 2 diabetes mellitus. Secondary analyses examined the risk associated with multiple-drug regimens, including stimulants and antidepressants, as well as individual SGAs. Retrospective national cohort study of Medicaid-enrolled youths between January 2003 and December 2007. In this observational study using national Medicaid Analytic eXtract data files, initiators and noninitiators of SGAs were identified in each month. Included in this study were US youths aged 10 to 18 years with a mental health diagnosis and enrolled in a Medicaid fee-for-service arrangement during the study. Those with chronic steroid exposure, a diagnosis of diabetes mellitus, or SGA use during a 1-year look-back period were ineligible. The mean follow-up time for all participants was 17.2 months. Youths were followed up until diagnosis of diabetes mellitus or end of follow-up owing to censoring caused by the transition into a Medicaid managed care arrangement or Medicaid ineligibility (the end of available data). Propensity weights were developed to balance observed demographic and clinical characteristics between exposure groups. Discrete failure time models were fitted using weighted logistic regression to estimate the risk for incident diabetes mellitus between initiators and noninitiators. A filled SGA prescription. Incident type 2 diabetes mellitus identified through visit and pharmacy claims during the observation period. Among 107 551 SGA initiators and 1 221 434 noninitiators, the risk for incident diabetes mellitus was increased among initiators (odds ratio [OR], 1.51; 95% CI, 1.35-1.69; P < .001). Compared with youths initiating only SGAs, the risk was higher among SGA initiators who used antidepressants concomitantly at the time of SGA initiation (OR, 1.54; 95% CI, 1.17-2.03; P = .002) but was not significantly different for SGA initiators who were concomitantly using stimulants. As compared with a reference group of risperidone initiators, the risk was higher among those initiating ziprasidone (OR, 1.61; 95% CI, 0.99-2.64; P = .06) and aripiprazole (OR, 1.58; 95% CI, 1.21-2.07; P = .001) but not quetiapine fumarate or olanzapine. The risk for incident type 2 diabetes mellitus was increased among youths initiating SGAs and was highest in those concomitantly using antidepressants. Compared with risperidone, newer antipsychotics were not associated with decreased risk.
    JAMA Pediatrics 04/2015; 169(4). DOI:10.1001/jamapediatrics.2015.0285